Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery and Targeting of the Signaling Controls of PNPLA3 to Effectively Reduce Transcription, Expression, and Function in Pre-Clinical NAFLD/NASH Settings.
Schwartz BE, Rajagopal V, Smith C, Cohick E, Whissell G, Gamboa M, Pai R, Sigova A, Grossman I, Bumcrot D, Sasidharan K, Romeo S, Sehgal A, Pingitore P. Schwartz BE, et al. Among authors: grossman i. Cells. 2020 Oct 7;9(10):2247. doi: 10.3390/cells9102247. Cells. 2020. PMID: 33036387 Free PMC article.
Pridopidine activates neuroprotective pathways impaired in Huntington Disease.
Geva M, Kusko R, Soares H, Fowler KD, Birnberg T, Barash S, -Wagner AM, Fine T, Lysaght A, Weiner B, Cha Y, Kolitz S, Towfic F, Orbach A, Laufer R, Zeskind B, Grossman I, Hayden MR. Geva M, et al. Among authors: grossman i. Hum Mol Genet. 2016 Sep 15;25(18):3975-3987. doi: 10.1093/hmg/ddw238. Epub 2016 Jul 27. Hum Mol Genet. 2016. PMID: 27466197 Free PMC article.
Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.
Kusko R, Dreymann J, Ross J, Cha Y, Escalante-Chong R, Garcia-Miralles M, Tan LJ, Burczynski ME, Zeskind B, Laifenfeld D, Pouladi M, Geva M, Grossman I, Hayden MR. Kusko R, et al. Among authors: grossman i. Mol Neurodegener. 2018 May 21;13(1):25. doi: 10.1186/s13024-018-0259-3. Mol Neurodegener. 2018. PMID: 29783994 Free PMC article.
Use of genetic technologies to compare medicines.
Kolitz SE, Towfic F, Grossman I, Hayden MR, Zeskind B. Kolitz SE, et al. Among authors: grossman i. Clin Genet. 2014 Nov;86(5):441-6. doi: 10.1111/cge.12462. Epub 2014 Sep 8. Clin Genet. 2014. PMID: 25046029 Review.
Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.
Masellis M, Collinson S, Freeman N, Tampakeras M, Levy J, Tchelet A, Eyal E, Berkovich E, Eliaz RE, Abler V, Grossman I, Fitzer-Attas C, Tiwari A, Hayden MR, Kennedy JL, Lang AE, Knight J; ADAGIO investigators. Masellis M, et al. Among authors: grossman i. Brain. 2016 Jul;139(Pt 7):2050-62. doi: 10.1093/brain/aww109. Epub 2016 May 13. Brain. 2016. PMID: 27190009 Clinical Trial.
Drug repurposing from the perspective of pharmaceutical companies.
Cha Y, Erez T, Reynolds IJ, Kumar D, Ross J, Koytiger G, Kusko R, Zeskind B, Risso S, Kagan E, Papapetropoulos S, Grossman I, Laifenfeld D. Cha Y, et al. Among authors: grossman i. Br J Pharmacol. 2018 Jan;175(2):168-180. doi: 10.1111/bph.13798. Epub 2017 May 18. Br J Pharmacol. 2018. PMID: 28369768 Free PMC article. Review.
100 results